1. Vera Therapeutics will present at the Immunology & Inflammation Summit. 2. The event occurs virtually from November 12-13, 2025. 3. One-on-one investor meetings are scheduled alongside the presentation. 4. Atacicept is Vera's leading product candidate targeting autoimmune diseases. 5. Vera holds exclusive rights to additional therapeutic proteins.
The upcoming presentation may attract investor interest and confidence in Vera's pipeline, similar to past biotech events that positively influenced stock prices.
The article directly relates to marketing Vera's innovations and engaging with potential investors, crucial for its performance.
Immediate market sentiment could shift leading up to and following the summit, influencing stock behavior in the short term.
BRISBANE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will present at the TD Cowen Immunology & Inflammation Summit, which is taking place virtually from November 12-13, 2025. The management team will also participate in one-on-one investor meetings.
Presentation Details:
Date: Thursday, November 13, 2025
Time: 1:30pm ET
Webcast: https://wsw.com/webcast/cowen185/vera/2021228
A replay of the event will be available for 90 days and can be accessed by visiting the "Investor Calendar" section of the Vera Therapeutics website.
About Vera Therapeutics
Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera Therapeutics' mission is to advance treatments that target the source of disease in order to change the standard of care for patients. Vera Therapeutics' lead product candidate is atacicept, a fusion protein self-administered at home as a subcutaneous once weekly injection that blocks both BAFF and APRIL, which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN and lupus nephritis. Beyond IgAN, Vera Therapeutics is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove clinically meaningful. In addition, Vera Therapeutics holds an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B-cell–mediated diseases. Vera Therapeutics is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus, which can have devastating consequences in kidney transplant recipients. Vera Therapeutics retains all global developmental and commercial rights to atacicept, VT-109, and MAU868. For more information, please visit www.veratx.com.
For more information, please contact:
Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com
Media Contact:
Debra Charlesworth
Vera Therapeutics
415-854-8051
corporatecommunications@veratx.com
